Transcription of The Stock Network Interview with 4DMedical (ASX:4DX), Founder, CEO and CTO, Dr Andreas Fouras
Lel Smits: 4D Medical, a global leader in respiratory imaging technology, has delivered a transformational period with the stock rising more than 2,000%, underpinned by rapid clinical adoption, regulatory milestones and strong institutional support. Most recently, 4D Medical announced the deployment of CTVQ at Mayo Clinic, the number one ranked hospital in the United States, marking one of the most significant institutional endorsements to date. This follows adoption across five other leading U.S. academic medical centers, highlighting extraordinary commercial momentum since FDA clearance in September last year.
Further strengthening its global position, 4D Medical secured CE Mark certification for CTVQ, enabling commercial rollout across Europe, alongside completing an $83 million placement to fund expansion and accelerate growth. Ahead of presenting at TIP Group’s Emerging Wealth Winners Conference, I’m joined by Founder, CEO and Chief Technology Officer, Dr. Andreas Foras, to discuss 4D Medical’s global expansion strategy and pathway to establishing CTVQ as a new standard of care globally. Andreas, welcome back to the Stock Network.
Andreas Fouras: Thanks. Great to be here, Lel.
Lel Smits: Now, 4D Medical has delivered a remarkable run with CTVQ now deployed across six leading U.S. academic medical centers, including the Mayo Clinic, the most recent announcement. What do you think this signals about the technology’s potential to become a new standard of care? And what’s next from here?
Andreas Fouras: It’s so exciting. I think we’ve worked for a long time to build VQ as our third generation product that is really a once in a generation opportunity for doctors to make a decision that has every key decision driver pointing in the same direction. And what I mean by that is it’s great for the doctor for their practice. It’s great for their patients. It’s great for the CFO of the hospital. Really, everybody gets a win when CTVQ is deployed at a healthcare system.
And we’ve been saying that for a while now. And I think it’s really great that everybody else, the rest of the market, whether it’s our shareholders or the folks at community hospitals across the United States, get to see that that really is the same opinion that’s held by folks like the doctors at Mayo Clinic.
Lel Smits: And Andreas, with CE Marks certification secured and an $83 million placement just completed to fund the European expansion, 4D Medical really is now positioned across two major healthcare markets. How are you approaching the rollout into Europe?
Andreas Fouras: It’s, this is once again, also very exciting. And to have now the resources for us to be able to deploy both in the United States and in the European markets at the same time without having to make any compromises is really great news for us. And I think that we continue to have a view that the US market is really important.
But if I kind of just give you the story of a number of leading doctors that I know, they’ll tend to do, say, four or five conferences a year, but two of those conferences might be in Europe. And so even when we’re looking at and we’re wanting to concentrate on those US doctors, if we’re not in Europe when they show up at those conferences, when we’re missing something like two out of five of the opportunities to talk to them each year. So I think I’m excited about the opportunity.
Europe is a really big market. And there are some, there are some kind of key differentiators about that market. But also being in Europe gives us the opportunity to have the eyeballs of those opinion leaders, those thought leaders in the United States.
And I think everybody who’s following us knows just how important it is for us to be the complete winners of that thought leadership layer for the US, for US doctors. And, you know, without getting too much into it right now today, I’m really looking forward to just, you know, in coming weeks or months, we have a really exciting plan about exactly how it is we’re going to deliver that European rollout. And, you know, I can’t wait to be able to share the fine details of that with everybody soon.
Lel Smits: And I’m sure you have a lot of people who can’t wait to hear those details. But for now, really, the focus, I imagine, will shift to commercialisation and revenue and scale. Can you walk us through the key inflection points over the next 12 months more broadly across the company, particularly around things like converting pilot deployments like the Mayo Clinic into full commercial contracts, expanding within existing hospital networks, and also driving reimbursement adoption?
Andreas Fouras: Yeah, look, that’s absolutely the playbook.
And at the start of it, of course, is, you know, driving the network effect. Doctors principally want to hear from other doctors that they trust and that they respect that technology works for them. And that really gives them the permission structure, it opens the door for them to then use it in their practice.
So of course, that’s absolutely why we’re starting with, you know, these key, the top 20 hospitals, top 50 hospitals in the United States, and so excited about how well we’ve done there. But, you know, we’ve been asking our investors to look and to measure us over calendar 2026. How are we doing in terms of winning those logos? And as I said, so far, we’ve been doing a great job.
But then, you know, of course, as we roll across from calendar 2026 into calendar 2027, our focus will be shifting from driving those network effects, creating those opportunities, and turning that into revenues. And I think that’s where a key point that’s sometimes missed of our strategy, you know, is getting missed by the market. And that is, these hospitals like the Cleveland Clinic, Mayo Clinic, they are in and of themselves, some of the biggest hospitals and hospital networks in the United States.
So just in and of themselves, they represent really very significant opportunities to drive large scale volume, large scale volumes of scans, and of course, you know, therefore really significant revenue growth for the company. So the relationships we’re building now with those doctors, not only facilitate them being, you know, part of that thought leadership network at the next conference, and the one after that, where they can be part of the story of convincing, you know, hundreds of hospitals behind them to join the queue, but they also are right there ready as opportunities for really big use, big volumes of the technology. It’s where we get that, you know, where we get that impact.
And then the third stage is, you know, those followers, the next hundred hospitals that come behind them. And of course, as you said, one of the key differentiators around VQ and where we’re is we’re positioned really well for revenue that to be driven through reimbursement. But at the same time, I am excited to say that, in fact, reimbursement is only just a small portion of the financial win that a site gets from taking up CTVQ.
There’s a number of other really significant economic wins, of course, that come after, you know, delivering better healthcare for the patient, like streamlining workflows through operating theatres and opening opportunities for different procedures to be delivered through nuclear medicine. So, in fact, you know, the reimbursement as generous as $650 per scan is, and as really as that’s great news, it’s in fact only just a small part of the win and why this really is becoming a no-brainer for so many hospitals across the US.
Lel Smits: Well, Andreas, I really appreciate the update today from Forty Medical and look forward to hearing more when you’re on stage at TIP Group’s Emerging Wealth Winners Conference in Sydney.
Andreas Fouras: I’m really looking forward to it too, Lel. Thanks a lot.
Ends